Cargando…

Surgical Rates for Crohn’s Disease are Decreasing: A Population-Based Time Trend Analysis and Validation Study

OBJECTIVES: Temporal changes for intestinal resections for Crohn’s disease (CD) are controversial. We validated administrative database codes for CD diagnosis and surgery in hospitalized patients and then evaluated temporal trends in CD surgical resection rates. METHODS: First, we validated Internat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Christopher, Moran, Gordon W, Benchimol, Eric I, Targownik, Laura E, Heitman, Steven J, Hubbard, James N, Seow, Cynthia H, Novak, Kerri L, Ghosh, Subrata, Panaccione, Remo, Kaplan, Gilaad G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Inflammatory Bowel Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729339/ https://www.ncbi.nlm.nih.gov/pubmed/29087396 http://dx.doi.org/10.1038/ajg.2017.394

Ejemplares similares

The Inflammatory Bowel Diseases and Ambient Air Pollution: A Novel Association
por: Kaplan, Gilaad G, et al.
Publicado: (2010)

Observational data from the adalimumab post‐marketing PYRAMID registry of patients with Crohn's disease who became pregnant: A post hoc analysis
por: Hart, Ailsa, et al.
Publicado: (2022)

Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study
por: Murthy, Sanjay K, et al.
Publicado: (2020)

The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

Trends in Epidemiology of Pediatric Inflammatory Bowel Disease in Canada: Distributed Network Analysis of Multiple Population-Based Provincial Health Administrative Databases
por: Benchimol, Eric I, et al.
Publicado: (2017)

Tight control for Crohn’s disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial
por: Panaccione, Remo, et al.
Publicado: (2020)

Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn’s disease (ANDANTE I and II)
por: Danese, Silvio, et al.
Publicado: (2019)

Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
por: Panés, Julian, et al.
Publicado: (2017)

Adalimumab for the treatment of fistulas in patients with Crohn’s disease
por: Colombel, J-F, et al.
Publicado: (2009)

Four-Year Maintenance Treatment With Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis: Data from ULTRA 1, 2, and 3
por: Colombel, Jean-Frederic, et al.
Publicado: (2014)

Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE
por: Panaccione, R, et al.
Publicado: (2013)

Crohn’s disease therapeutic dietary intervention (CD-TDI): study protocol for a randomised controlled trial
por: Raman, Maitreyi, et al.
Publicado: (2022)

Proteomic analysis of ascending colon biopsies from a paediatric inflammatory bowel disease inception cohort identifies protein biomarkers that differentiate Crohn's disease from UC
por: Starr, Amanda E, et al.
Publicado: (2017)

A microbial signature for Crohn's disease
por: Pascal, Victoria, et al.
Publicado: (2017)

Crohn's disease related strictures in cross‐sectional imaging: More than meets the eye?
por: Sleiman, Joseph, et al.
Publicado: (2022)

The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease
por: Vande Casteele, Niels, et al.
Publicado: (2015)

Bacterial protein signals are associated with Crohn’s disease
por: Juste, Catherine, et al.
Publicado: (2014)

Treat‐to‐target and sequencing therapies in Crohn's disease
por: Garcia, Nicole M., et al.
Publicado: (2022)

Rural and Urban Residence During Early Life is Associated with Risk of Inflammatory Bowel Disease: A Population-Based Inception and Birth Cohort Study
por: Benchimol, Eric I, et al.
Publicado: (2017)

PICaSSO virtual electronic chromendoscopy accurately reflects combined endoscopic and histological assessment for prediction of clinical outcomes in ulcerative colitis
por: Nardone, Olga Maria, et al.
Publicado: (2022)

SHIP deficiency causes Crohn's disease-like ileitis
por: Kerr, William G, et al.
Publicado: (2010)

A phase II study of laquinimod in Crohn's disease
por: D'Haens, Geert, et al.
Publicado: (2015)

Inability to walk: a rare presentation of Crohn’s disease
por: Hoekstra, Elmer, et al.
Publicado: (2020)

Variables associated with progression of moderate-to-severe Crohn’s disease
por: Sacramento, Carolina da Silva Beda, et al.
Publicado: (2022)

New endoscopic tools in inflammatory bowel disease
por: Nardone, Olga Maria, et al.
Publicado: (2022)

Factors affecting outcomes in Crohn's disease over 15 years
por: Cosnes, Jacques, et al.
Publicado: (2012)

A novel unconventional T cell population enriched in Crohn’s disease
por: Rosati, Elisa, et al.
Publicado: (2022)

Creeping fat formation and interaction with intestinal disease in Crohn's disease
por: Yin, Yi, et al.
Publicado: (2022)

Development and initial psychometric validation of a patient-reported outcome measure for Crohn’s perianal fistula: the Crohn’s Anal Fistula Quality of Life (CAF-QoL) scale
por: Adegbola, Samuel O, et al.
Publicado: (2021)

Population pharmacokinetics‐pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease
por: Rosario, M., et al.
Publicado: (2015)

Developing a core outcome set for fistulising perianal Crohn’s disease
por: Sahnan, Kapil, et al.
Publicado: (2019)

Perianal fistulizing Crohn's disease and overall risk of cancer: No red flag
por: McLellan, Paul, et al.
Publicado: (2023)

Therapeutic Effect of Vitamin D Supplementation in a Pilot Study of Crohn's Patients
por: Yang, Linlin, et al.
Publicado: (2013)

Study of the Viral and Microbial Communities Associated With Crohn's Disease: A Metagenomic Approach
por: Pérez-Brocal, Vicente, et al.
Publicado: (2013)

Transmural remission improves clinical outcomes up to 5 years in Crohn's disease
por: Fernandes, Samuel Raimundo, et al.
Publicado: (2022)

Understanding progression of strictures in ileal Crohn's disease—The importance of setting methodological standards
por: Tavares de Sousa, Helena, et al.
Publicado: (2022)

Editorial: Postoperative management of Crohn's disease: One size does not fit all
por: Domènech, Eugeni, et al.
Publicado: (2023)

Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease
por: Buisson, Anthony, et al.
Publicado: (2021)

The impact of ustekinumab on extraintestinal manifestations of Crohn's disease: A post hoc analysis of the UNITI studies
por: Narula, Neeraj, et al.
Publicado: (2021)

Validation of stricture length, duration and obstructive symptoms as predictors for intervention in ileal stricturing Crohn's disease
por: El Ouali, Sara, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6q4g748phu9o8ijhmupf5tgns0